Can we make smart choices between OLS and contaminated IV methods?

In the outcomes research and comparative effectiveness research literature, there are strong cautionary tales on the use of instrumental variables (IVs) that may influence the newly initiated to shun this premier tool for casual inference without properly weighing their advantages. It has been recommended that IV methods should be avoided if the instrument is not econometrically perfect. The fact that IVs can produce better results than naïve regression, even in nonideal circumstances, remains underappreciated. In this paper, we propose a diagnostic criterion and related software that can be used by an applied researcher to determine the plausible superiority of IV over an ordinary least squares (OLS) estimator, which does not address the endogeneity of a covariate in question. Given a reasonable lower bound for the bias arising out of an OLS estimator, the researcher can use our proposed diagnostic tool to confirm whether the IV at hand can produce a better estimate (i.e., with lower mean square error) of the true effect parameter than the OLS, without knowing the true level of contamination in the IV.

[1]  Jeffrey A. Lieberman,et al.  Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder , 2002 .

[2]  J. Stock,et al.  Retrospectives Who Invented Instrumental Variable Regression , 2003 .

[3]  Charles E McCulloch,et al.  Efficacy of Phototherapy for Newborns with Hyperbilirubinemia , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  J. Stock,et al.  Instrumental Variables Regression with Weak Instruments , 1994 .

[5]  D. Revicki,et al.  Olanzapine versus Risperidone , 2000, PharmacoEconomics.

[6]  David A. Jaeger,et al.  Problems with Instrumental Variables Estimation when the Correlation between the Instruments and the Endogenous Explanatory Variable is Weak , 1995 .

[7]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[8]  James H. Stock,et al.  Who Invented Instrumental Variable Regression , 2003 .

[9]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[10]  Partha Deb,et al.  When and how to use instrumental variables in palliative care research. , 2009, Journal of palliative medicine.

[11]  Zhongyun Zhao,et al.  Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia , 2004, Current medical research and opinion.

[12]  Sebastian Schneeweiss,et al.  Preference-Based Instrumental Variable Methods for the Estimation of Treatment Effects: Assessing Validity and Interpreting Results , 2007, The international journal of biostatistics.

[13]  Christopher R. Taber,et al.  Selection on Observed and Unobserved Variables: Assessing the Effectiveness of Catholic Schools , 2000, Journal of Political Economy.

[14]  David J Vanness,et al.  Some cautions on the use of instrumental variables estimators in outcomes research: how bias in instrumental variables estimators is affected by instrument strength, instrument contamination, and sample size. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Michael P. Murray Avoiding Invalid Instruments and Coping with Weak Instruments , 2006 .